Physician profile
Michael Flisak
NPI 1548426943
$11,229.90
in general payments reported to CMS, 2019-2025
28 companies · $60.06 in 2025
The $60.06 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,704 · 2020: $75.04 · 2021: $415 · 2022: $405 · 2023: $651 · 2024: $919 · 2025: $60.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829 · Travel and Lodging: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.56 |
| Travel and Lodging | $801.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,152.67 | 2019 | |
| Abbott Laboratories | $1,073.98 | 2022-2024 | Perclose Proglide, Amplatzer Amulet, Aveir |
| Astrazeneca Pharmaceuticals LP | $227.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.00 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.07 | 2019-2023 | Lifevest |
| Medtronic, INC. | $180.06 | 2021-2024 | Corevalve Evolut R, In.Pact Admiral, Micra |
| Cardiovascular Systems INC. | $163.94 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $160.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $146.08 | 2019 | |
| Bard Peripheral Vascular, INC. | $116.80 | 2022-2024 | Rotarexs 6 F X 135 Cm, Lutonix Drug Coated Balloon, Lifestream |
| Philips North America LLC | $94.63 | 2019-2023 | |
| Angiodynamics, INC. | $82.92 | 2022 | |
| Pfizer INC. | $82.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $55.96 | 2019-2024 | |
| Abiomed | $45.56 | 2022-2023 | Impella |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $29.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.42 | 2019 | |
| Gilead Sciences, INC. | $25.07 | 2019 | |
| Merit Medical Systems INC | $24.52 | 2022 | |
| Novo Nordisk INC | $23.67 | 2023 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $22.62 | 2019 | |
| Scpharmaceuticals INC. | $22.48 | 2025 | |
| Amgen INC. | $18.19 | 2019 | |
| Livanova USA, INC. | $16.70 | 2020 | |
| Chiesi USA, INC. | $16.08 | 2022 | |
| Inari Medical, INC. | $14.51 | 2019 | |
| Ekos Corporation | $13.55 | 2019 | |
| Amarin Pharma, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flisak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.